Neuropsychoanalysis Association to host conference on depression

NewsGuard 100/100 Score

Lessons from the treatment battlefield and new research

The Neuropsychoanalysis Association (NPSA) is hosting a conference for researchers and clinicians on depression, "Towards a Real Understanding of Depression: Lessons from the Treatment Battlefeld and New Research," on Friday, November 1, 2013 from 9:00 am to 6:00 pm at the Icahn School of Medicine at Mount Sinai, The Bonnie and Kenneth Davis Auditorium, 1470 Madison Avenue (between 101st and 102nd Streets) in New York City. Recent meta-analyses have indicated that SSRIs, although extremely effective for some, have not fulfilled their original promise of being a broadly successful anti-depressant. This full day program will be an interdisciplinary event focusing on pioneering work in biological psychiatry, basic neuroscience and other fields aimed at discovering new treatments for depression, including what have we learned so far, future directions; and how to use the data from new treatment research to hone in on the core pathophysiology of depression and models of brain organization which underlie approaches to treatment.

Featured keynote speakers include Steven Paul (Cornell), "Why we need new and better antidepressants: lessons from the treatment and clinical research battlefield;" and Jaak Panksepp (Washington State University), "Pre-clinical affective neuroscience modelling of depression, and evaluation of three new antidepressant strategies."

WHAT:Towards a Real Understanding of Depression: Lessons from the Treatment Battlefield and New Research

WHEN:Friday, November 1, 2013
9:00 am - 6:00 pm

WHERE:Icahn School of Medicine at Mount Sinai, Bonnie and Kenneth Davis Auditorium
1470 Madison Avenue (between 101st and 102nd Streets), NYC

REGISTRATION:Addavail Coslett, Associate Dir. Programming & Development [email protected] or 212-572-3693

PROGRAM SPEAKERS:

Maggie Zellner, The Neuropsychoanalysis Foundation

Ronald Duman (Yale), Neurobiology of stress, depression and antidepressants: Remodeling synaptic connections

James Murrough (Mt Sinai), Ketamine as a fast-acting antidepressant

Elizabeth Fitelson (Columbia), Estrogen and other hormones in depression

Dan Javitt, (Columbia), Depression from a glutamatergic perspective: the interaction of neuromodulation and brain glutamatergic systems

Wayne Goodman (Mt. Sinai), DBS treatment for depression

Dan Iosifescu (Mt. Sinai School of Medicine), Non-invasive neurostimulation for the treatment of major depression

Cori Bargmann (Rockefeller), The BRAIN Initiative: Understanding brain circuits as a foundation for accelerating human neuroscience

Baruch Fishman (New York-Presbyterian/Weill Cornell), CBT perspectives on depression and treatment

Mark Solms (University of Cape Town), Psychoanalytic perspectives on depression and the panic-shutdown hypothesis

Andrew Gerber (Columbia), Empirical outcome studies of psychodynamic and cognitive behavioral therapies, and brain effects of treatment

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Metabolic markers tied to increased risk of depression and anxiety, study finds